Titanocene Y (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Titanocene Y" in English language version.

refsWebsite

Global rank English rank

20doi.org

2^nd place

13nih.gov

4^th place

7semanticscholar.org

11^th place

8^th place

doi.org

Sweeney NJ, Mendoza O, Müller-Bunz H, Pampillón C, Rehmann FJ, Strohfeldt K, Tacke M (2005). "Novel benzyl substituted titanocene anti-cancer drugs". Journal of Organometallic Chemistry. 690 (21–22): 4537–4544. doi:10.1016/j.jorganchem.2005.06.039.
Köpf H, Köpf-Maier P (1979). "Titanocene dichloride--the first metallocene with cancerostatic activity". Angew. Chem. Int. Ed. Engl. 18 (6): 477–478. doi:10.1002/anie.197904771. PMID 111586.
Kröger N, Kleeberg UR, Mross K, Edler L, Hossfeld DK (2000). "Phase II Clinical Trial of Titanocene Dichloride in Patients with Metastatic Breast Cancer". Onkologie. 23 (1): 60–62. doi:10.1159/000027075. S2CID 72817279.
Lümmen G, Sperling H, Luboldt H, Otto T, Rübben H (1998). "Phase II trial of titanocene dichloride in advanced renal-cell carcinoma". Cancer Chemother. Pharmacol. 42 (5): 415–417. doi:10.1007/s002800050838. PMID 9771957. S2CID 2724249.
Allen OR, Croll L, Gott AL, Knox RJ, McGowan PC (2004). "Functionalized Cyclopentadienyl Titanium Organometallic Compounds as New Antitumor Drugs". Organometallics. 23 (2): 288–292. doi:10.1021/om030403i.
Strohfeldt K, Tacke M (2008). "Bioorganometallic fulvene-derived titanocene anti-cancer drugs". Chem Soc Rev. 37 (6): 1174–1187. doi:10.1039/b707310k. PMID 18497930.
O'Connor K, Gill C, Tacke M, Rehmann FJ, Strohfeldt K, Sweeney N, Fitzpatrick JM, Watson RW (2006). "Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells". Apoptosis. 11 (7): 1205–1214. doi:10.1007/s10495-006-6796-1. PMID 16699961. S2CID 31009957.
Weber H, Claffey J, Hogan M, Pampillón C, Tacke M (2008). "Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay". Toxicol in Vitro. 22 (2): 531–534. doi:10.1016/j.tiv.2007.09.014. PMID 17981007.
Kelter G, Sweeney NJ, Strohfeldt K, Fiebig HH, Tacke M (2005). "In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes". Anticancer Drugs. 16 (10): 1091–1098. doi:10.1097/00001813-200511000-00008. PMID 16222151. S2CID 44409481.
Oberschmidt O, Hanauske AR, Pampillón C, Sweeney NJ, Strohfeldt K, Tacke M (2007). "Antiproliferative activity of Titanocene Y against tumor colony-forming units". Anticancer Drugs. 18 (3): 317–321. doi:10.1097/CAD.0b013e3280115f86. PMID 17264765. S2CID 22670179.
Vessières A, Plamont MA, Cabestaing C, Claffey J, Dieckmann S, Hogan M, Müller-Bunz H, Strohfeldt K, Tacke M (2009). "Proliferative and anti-proliferative effects of titanium- and iron-based metallocene anti-cancer drugs". Journal of Organometallic Chemistry. 694 (6): 874–879. doi:10.1016/j.jorganchem.2008.11.071.
Lally G, Deally A, Hackenberg F, Quinn SJ, Tacke M (2013). "Titanocene Y – Transport and Targeting of an Anticancer Drug Candidate". Letters in Drug Design & Discovery. 10 (8): 675–682. doi:10.2174/15701808113100890027.
Tacke M (2008). "The Interaction of Titanocene Y with Double-Stranded DNA: A Computational Study". Letters in Drug Design & Discovery. 5 (5): 332–335. doi:10.2174/157018008784912036.
Erxleben A, Claffey J, Tacke M (2010). "Binding and hydrolysis studies of antitumoural titanocene dichloride and Titanocene Y with phosphate diesters". J. Inorg. Biochem. 104 (4): 390–396. doi:10.1016/j.jinorgbio.2009.11.010. PMID 20036426.
Kater L, Claffey J, Hogan M, Jesse P, Kater B, Strauss S, Tacke M, Prokop A (2012). "The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming multiple drug resistance in malignant leukemia cells". Toxicol in Vitro. 26 (1): 119–124. doi:10.1016/j.tiv.2011.09.010. PMID 21986259.
Hilger A, Alex D, Deally A, Gleeson B, Tacke M, Ralf (2011). "Titanocene Y and Vanadocene Y: Platinum Resistance-Breaking Cytotoxic and DNA-Targeting Anticancer Drug Candidates". Letters in Drug Design & Discovery. 8 (10): 904–910. doi:10.2174/157018011797655241.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Bannon JH, Fichtner I, O'Neill A, Pampillón C, Sweeney NJ, Strohfeldt K, Watson RW, Tacke M, Mc Gee MM (2007). "Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo". Br. J. Cancer. 97 (9): 1234–1241. doi:10.1038/sj.bjc.6604021. PMC 2360460. PMID 17923871.
Dowling CM, Claffey J, Cuffe S, Fichtner I, Pampillón C, Sweeney NJ, Strohfeldt K, Watson RW, Tacke M (2008). "Antitumor activity of Titanocene Y in xenografted PC3 tumors in mice". Letters in Drug Design & Discovery. 5 (2): 141–144. doi:10.2174/157018008783928463.
Beckhove P, Oberschmidt O, Hanauske AR, Pampillón C, Schirrmacher V, Sweeney NJ, Strohfeldt K, Tacke M (2007). "Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice". Anticancer Drugs. 18 (3): 311–315. doi:10.1097/CAD.0b013e328010a6f7. PMID 17264764. S2CID 42898975.
Fichtner I, Pampillón C, Sweeney NJ, Strohfeldt K, Tacke M (2006). "Antitumor activity of Titanocene Y in xenografted CAKI-1 tumors in mice". Anticancer Drugs. 17 (3): 333–336. doi:10.1097/00001813-200603000-00012. PMID 16520662. S2CID 45195878.

nih.gov

pubmed.ncbi.nlm.nih.gov

Köpf H, Köpf-Maier P (1979). "Titanocene dichloride--the first metallocene with cancerostatic activity". Angew. Chem. Int. Ed. Engl. 18 (6): 477–478. doi:10.1002/anie.197904771. PMID 111586.
Lümmen G, Sperling H, Luboldt H, Otto T, Rübben H (1998). "Phase II trial of titanocene dichloride in advanced renal-cell carcinoma". Cancer Chemother. Pharmacol. 42 (5): 415–417. doi:10.1007/s002800050838. PMID 9771957. S2CID 2724249.
Strohfeldt K, Tacke M (2008). "Bioorganometallic fulvene-derived titanocene anti-cancer drugs". Chem Soc Rev. 37 (6): 1174–1187. doi:10.1039/b707310k. PMID 18497930.
O'Connor K, Gill C, Tacke M, Rehmann FJ, Strohfeldt K, Sweeney N, Fitzpatrick JM, Watson RW (2006). "Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells". Apoptosis. 11 (7): 1205–1214. doi:10.1007/s10495-006-6796-1. PMID 16699961. S2CID 31009957.
Weber H, Claffey J, Hogan M, Pampillón C, Tacke M (2008). "Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay". Toxicol in Vitro. 22 (2): 531–534. doi:10.1016/j.tiv.2007.09.014. PMID 17981007.
Kelter G, Sweeney NJ, Strohfeldt K, Fiebig HH, Tacke M (2005). "In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes". Anticancer Drugs. 16 (10): 1091–1098. doi:10.1097/00001813-200511000-00008. PMID 16222151. S2CID 44409481.
Oberschmidt O, Hanauske AR, Pampillón C, Sweeney NJ, Strohfeldt K, Tacke M (2007). "Antiproliferative activity of Titanocene Y against tumor colony-forming units". Anticancer Drugs. 18 (3): 317–321. doi:10.1097/CAD.0b013e3280115f86. PMID 17264765. S2CID 22670179.
Erxleben A, Claffey J, Tacke M (2010). "Binding and hydrolysis studies of antitumoural titanocene dichloride and Titanocene Y with phosphate diesters". J. Inorg. Biochem. 104 (4): 390–396. doi:10.1016/j.jinorgbio.2009.11.010. PMID 20036426.
Kater L, Claffey J, Hogan M, Jesse P, Kater B, Strauss S, Tacke M, Prokop A (2012). "The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming multiple drug resistance in malignant leukemia cells". Toxicol in Vitro. 26 (1): 119–124. doi:10.1016/j.tiv.2011.09.010. PMID 21986259.
Bannon JH, Fichtner I, O'Neill A, Pampillón C, Sweeney NJ, Strohfeldt K, Watson RW, Tacke M, Mc Gee MM (2007). "Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo". Br. J. Cancer. 97 (9): 1234–1241. doi:10.1038/sj.bjc.6604021. PMC 2360460. PMID 17923871.
Beckhove P, Oberschmidt O, Hanauske AR, Pampillón C, Schirrmacher V, Sweeney NJ, Strohfeldt K, Tacke M (2007). "Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice". Anticancer Drugs. 18 (3): 311–315. doi:10.1097/CAD.0b013e328010a6f7. PMID 17264764. S2CID 42898975.
Fichtner I, Pampillón C, Sweeney NJ, Strohfeldt K, Tacke M (2006). "Antitumor activity of Titanocene Y in xenografted CAKI-1 tumors in mice". Anticancer Drugs. 17 (3): 333–336. doi:10.1097/00001813-200603000-00012. PMID 16520662. S2CID 45195878.

ncbi.nlm.nih.gov

Bannon JH, Fichtner I, O'Neill A, Pampillón C, Sweeney NJ, Strohfeldt K, Watson RW, Tacke M, Mc Gee MM (2007). "Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo". Br. J. Cancer. 97 (9): 1234–1241. doi:10.1038/sj.bjc.6604021. PMC 2360460. PMID 17923871.

semanticscholar.org

api.semanticscholar.org

Kröger N, Kleeberg UR, Mross K, Edler L, Hossfeld DK (2000). "Phase II Clinical Trial of Titanocene Dichloride in Patients with Metastatic Breast Cancer". Onkologie. 23 (1): 60–62. doi:10.1159/000027075. S2CID 72817279.
Lümmen G, Sperling H, Luboldt H, Otto T, Rübben H (1998). "Phase II trial of titanocene dichloride in advanced renal-cell carcinoma". Cancer Chemother. Pharmacol. 42 (5): 415–417. doi:10.1007/s002800050838. PMID 9771957. S2CID 2724249.
O'Connor K, Gill C, Tacke M, Rehmann FJ, Strohfeldt K, Sweeney N, Fitzpatrick JM, Watson RW (2006). "Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells". Apoptosis. 11 (7): 1205–1214. doi:10.1007/s10495-006-6796-1. PMID 16699961. S2CID 31009957.
Kelter G, Sweeney NJ, Strohfeldt K, Fiebig HH, Tacke M (2005). "In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes". Anticancer Drugs. 16 (10): 1091–1098. doi:10.1097/00001813-200511000-00008. PMID 16222151. S2CID 44409481.
Oberschmidt O, Hanauske AR, Pampillón C, Sweeney NJ, Strohfeldt K, Tacke M (2007). "Antiproliferative activity of Titanocene Y against tumor colony-forming units". Anticancer Drugs. 18 (3): 317–321. doi:10.1097/CAD.0b013e3280115f86. PMID 17264765. S2CID 22670179.
Beckhove P, Oberschmidt O, Hanauske AR, Pampillón C, Schirrmacher V, Sweeney NJ, Strohfeldt K, Tacke M (2007). "Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice". Anticancer Drugs. 18 (3): 311–315. doi:10.1097/CAD.0b013e328010a6f7. PMID 17264764. S2CID 42898975.
Fichtner I, Pampillón C, Sweeney NJ, Strohfeldt K, Tacke M (2006). "Antitumor activity of Titanocene Y in xenografted CAKI-1 tumors in mice". Anticancer Drugs. 17 (3): 333–336. doi:10.1097/00001813-200603000-00012. PMID 16520662. S2CID 45195878.